The value of the NGAL biomarker in predicting and evaluating the effectiveness of therapy in patients with diabetes mellitus type 2 and chronic kidney disease 1-4 ST

Background. Neutrophil gelatinase-associated lipocalin (NGAL) is a useful new biomarker for the early diagnosis of acute kidney injury, the authors noted, when marker values exceed the normal range, ranging from 50-150 ng/ml, possible damage. Values from 150 to 1000 ng/ml indicate the presence of tubular damage, and more than 1000 ng/ml - dangerous tubular damage. The purpose of the study is to find the importance of the NGAL biomarker in predicting and assessing the effectiveness of therapy in patients with type 2 diabetes and CKD stages 1-4. Research methodology: The study material is presented by analysis of data from 40 patients with type 2 diabetes and CKD stages 1-4. Research results. In CKD stages 1, 2 and 3, as the degree of CKD progressed, no significant decrease in the level of NGAL in urine was detected. The significant decrease in NGAL in urine that we identified was found in 10 patients with stage 4 CKD, which is probably associated with the onset of renal fibrosis.